Latham & Watkins Leads on US$400 Million Debt Financing Facility for Cogent Biosciences

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, has announced it has secured a debt financing facility of up to US$400 million with credit funds managed by SLR Capital Partners, LLC (SLR). An initial tranche of US$50 million was drawn at closing, with future tranches available based on the achievement of key clinical and commercial milestones aligned with Cogent’s growth strategy.

Latham & Watkins LLP represents SLR in the transaction with a deal team led by partners Dan Van Fleet and Haim Zaltzman, with associates Erin Cusenbary and Dominic Gambino. Advice was also provided on tax matters by partner Eric Cho; on FDA/regulatory matters by counsel Chad Jennings; on capital markets matters by partners Eric Rice and Reza K. Mojtabaee-Zamani; on security matters by counsel Emily Leong Yu, with senior paralegal Tiffany Vacca; and on IP matters by senior paralegal Rhonda DeLeon.